Antifungal pharmacotherapy for invasive mould infections (Q35058091)

6 August 2017

1 reference

title

Antifungal pharmacotherapy for invasive mould infections (English)

1 reference

6 August 2017

0 references

4

John R Perfect

1 reference

6 August 2017

Elizabeth Dodds Ashley

series ordinal

2

object named as

Elizabeth S Dodds Ashley

1 reference

6 August 2017

Jason C Gallagher

1

1 reference

6 August 2017

Richard H Drew

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Expert Opinion on Pharmacotherapy

6 August 2017

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

147-164

1 reference

Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Aspergillosis: The most common community-acquired pneumonia with gram-negative Bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Nosocomial aspergillosis is waterborne

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Safety of aerosolized amphotericin B lipid complex in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Invasive aspergillosis in 2002: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

21 January 2018

Intravenous itraconazole

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Combination immunotherapy and antifungal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Adjunctive immune therapy for fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Pulmonary scedosporium infection following lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Disseminated phaeohyphomycosis: review of an emerging mycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Septic arthritis due to Scedosporium apiospermum: case report and review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Disseminated infection by Scedosporium prolificans: an emerging fatality among haematology patients. Case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Scedosporium apiospermum fungemia in a lung transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Treatment of Scedosporium apiospermum brain abscesses with posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Chronic infection due to Fusarium oxysporum mimicking lupus vulgaris: case report and review of cutaneous involvement in fusariosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Fusarium infection after solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Diabetic ketoacidosis and rhino-orbital mucormycosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Liver and brain mucormycosis in a diabetic patient type II successfully treated with liposomial amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Survival after rhino-orbital-cerebral mucormycosis in an immunocompetent patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Paecilomyces variotii in a pediatric patient with lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Penicilliosis marneffei and pythiosis: emerging tropical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Penicillium marneffei: types and drug susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Efficacy of voriconazole in treatment of murine pulmonary blastomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Cerebral phaeohyphomycosis due to a novel species: report of a case and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Amphotericin B use in a community hospital, with special emphasis on side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Effect of salt supplementation on amphotericin B nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Lipid formulations of amphotericins: are you a lumper or a splitter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Interactions between triazoles and amphotericin B against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.2.147

21 January 2018

Identifiers

DOI

10.1517/14656566.4.2.147

1 reference

6 August 2017

1 reference